Klingt verlockend:
•Reloxaliase has a >80% probability of reaching commercial stage after reviewing the results of the URIROX-1 trial and the design of the URIROX-2 trial.
•Reloxaliase has a shot at $22 billion/year revenue opportunity just in the U.S. with a competitive advantage, yet the company's pipeline is being valued at just $45M.
•The stock is at a good Buy level after the recent pullback. Rating Buy, first price target=$4.50/share, time-frame=1-2 years.
seekingalpha.com/article/...maceuticals-rating-this-stock-buy
Latest News:
www.rttnews.com/3050506/...on-watch-alna-trims-workforce.aspx
Pipeline:
www.allenapharma.com/pipeline
•Reloxaliase has a >80% probability of reaching commercial stage after reviewing the results of the URIROX-1 trial and the design of the URIROX-2 trial.
•Reloxaliase has a shot at $22 billion/year revenue opportunity just in the U.S. with a competitive advantage, yet the company's pipeline is being valued at just $45M.
•The stock is at a good Buy level after the recent pullback. Rating Buy, first price target=$4.50/share, time-frame=1-2 years.
seekingalpha.com/article/...maceuticals-rating-this-stock-buy
Latest News:
www.rttnews.com/3050506/...on-watch-alna-trims-workforce.aspx
Pipeline:
www.allenapharma.com/pipeline